Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1669-1673

  McKenzie, Katherine E ^a   Siva, Amara ^a   Maier, Sabine ^b   Runnebaum, Ingo B ^b   Seshadri, Ram ^c   Sukumar, Saraswati ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER STAGING; CELL CYCLE; CLINICAL ARTICLE; COHORT ANALYSIS; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; STOP CODON; TISSUE CULTURE; TUMOR VOLUME;

AUSTRALIA; BREAST NEOPLASMS; CELL CYCLE; CLONING, MOLECULAR; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0030861086     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression Cell 75: 817-825, 1993.
2. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
3. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
4. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 260: 1821-1828, 1994.
5. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 23: 6304-6311, 1991.
6. 1 cyclin-dependent kinases. Cell. 75: 805-816, 1993.
7. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
8. Johnson, M., Dimitrov, D., Vojta, P. J., Barrett, J. C., Noda, A., Pereira-Smith, O. M., and Smith, J. R. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol. Carcinog., 11: 59-64, 1994.
9. Lowe, S. W., Schmitt, E. M., Smith S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse. Nature (Lond.), 362: 847-849, 1993.
10. Balbin, M., Hannon, G. J., Pendas, A. M., Ferrando, A. A., Vizoso, F., Fueyo, A., and Lopez-Otin, C. Functional analysis of a p21WAF1/ CIP1/SDI1 mutant (arg94→Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J. Biol. Chem., 277: 15782-15784, 1996.
11. Blin, N., and Stafford, D. W. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res., 3: 2303-2308, 1976.
12. Glebov, O. K., McKenzie, K. E., White, C. A., and Sukumar, S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res., 54: 3703-3709, 1994.
13. Runnebaum, I. B., Nagarajan, M., Bowman, M., Soto, D., and Sukumar, S. Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl. Acad. Sci. USA, 88: 10657-10661, 1991.
14. Soto, D., and Sukumar, S. Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Methods Appl., 2: 96-98, 1992.
15. Marchetti, A., Buttitta, F., Pellegrini, S., Bertacca, G., Lori, A., and Bevilacqua, G. Absence of somatic mutations in the coding region of the Waf1/Cip1 gene in human breast, ovarian and lung carcinomas: a polymorphism at codon 31. Int. J. Oncol., 6: 187-189, 1995.
16. Sun, Y., Hildesheim, A., Li, H., Li, Y., Chen, J-Y., Cheng, Y-J., Hayes, R. B., Rothman, N., Bi, W-F., Cao, Y., Yao, K-T., Lanier, A., Hegamyer, P. G., El-Deiry, W. S., Xiong, Y., and Colburn, N. H. No point mutation but a codon 31Ser→Arg polymorphism of the WAF-1/ CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): The polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol., Biomarkers & Prev., 4: 261-267, 1995.
17. Chedid, M., Michieli, P., Lengel, C., Huppi, K., and Givol, D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/ CIP1. Oncogene, 9: 3021-3024, 1994.
18. Mousses, S., Ozcelik, H., Lee, P. D., Malkin, D., Bull, S. B., and Andrulis, I. L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet., 4: 1089-1092, 1995.
19. Musgrove, E. A., Lilischkis, R., Cornish, A. L., Lee, C. S., Setlur, V., Seshadri, R., and Sutherland, R. L. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int. J. Cancer, 63: 584-591, 1995.
20. Barak, Y., and Oren, M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J., 11: 2115-2121, 1992.
21. Weintraub, H., Hauschka, S., and Tapscott, S. J. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA, 88: 4570-4571, 1991.
22. Shiohara, M., el-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., L, C. D., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
23. Shimizu, T., Miwa, W., Nakamori, S., Ishikawa, O., Konishi, Y., and Sekiya, T. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn. J. Cancer Res., 87: 275-278, 1996.
24. Wan, M., Cofer, K. F., and Dubeau, L. WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Br. J. Cancer, 73: 1398-1400, 1996.
25. Li, L., Laurent-Puig, P., Salmon, R. J., Thomas, G., and Hamelin, R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene, 10: 599-601, 1995.
26. Bhatia, K., Fan, S., Spangler, G., Weintraub, M., O'Connor, P. M., Judde, J. G., and Magrath, I. A mutant p21 cyclin-dependent kinase inhibitor isolated from Burkitt's lymphoma. Cancer Res., 55: 1431-1435, 1995.
27. 1 checkpoint control. Cell, 82: 675-684, 1995.
28. Luo, Y., Hurwitz, J., and Massague, J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (Lond.), 375: 159-161, 1995.
29. Chen, J., Jackson, P. K., Kirschner, M. W., and Dutta, A. Separate domains of p21 involved in the inhibition of Cdk kinases and PCNA. Nature (Lond.), 374: 386-388, 1995.
30. Nakanishi, M., Robetorye, R. S., Pereira-Smith, O. M., and Smith, J. R. The C-terminal region of p21sdi1/waf1/cip1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J. Biol. Chem., 270: 17060-17063, 1995.
31. Nakanishi, M., Robetorye, R. S., Adami, G. R., Pereira-Smith, O. M., and Smith, J. R. Identification of the active region of the DNA synthesis inhibitory gene p21/Sdi1/CIP1/WAF1. EMBO J., 14: 555-563, 1995.
32. Mazars, R., Spinardi, L., BenCheikh, M., Simony-Lafontaine, J., Jeanteur, P., and Theillet, C. p53 mutations occur in aggressive breast cancer. Cancer Res., 52: 3918-3923, 1992.
33. Seshadri, R., Leong, A. S., McCaul, K., Figaira, F. A., Setlur, V., and Horsfall, D. J. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int. J. Cancer, 69: 135-141, 1996.
34. Davidoff, A. M., Herndon, J. E., II, Glover, N. S., Kerns, B-J. M., Pence, J. C., Iglehart, J. D., and Marks, J. R. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery (St. Louis), 110: 259-264, 1991.